Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood (2024) 144 (3): 262–271.

https://doi.org/10.1182/blood.2024023944

Published: 2024

Includes: Supplemental data

Journal Articles

Unraveling MCL biology to understand resistance and identify vulnerabilities

clémentine Sarkozy, Benoit Tessoulin, David Chiron

Blood blood.2023022351.

https://doi.org/10.1182/blood.2023022351

Published: 2024

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood (2023) 142 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2023-173815

Published: 2023

Journal Articles

Multi-Dimensional Molecular and Tumor-Microenvironment Analysis of Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 172.

https://doi.org/10.1182/blood-2023-174139

Published: 2023

Journal Articles

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clementine Sarkozy, Mary Callanan, Catherine Thieblemont, Lucie Oberic, Barbara Burroni, Krimo Bouabdallah, Gandhi Laurent Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Houot, Franck Morschhauser, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 980.

https://doi.org/10.1182/blood-2023-174416

Published: 2023

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Clementine Sarkozy, Thierry Jo Molina, Roch Houot, Sydney Dubois, Gian Matteo Pica, Philippe Ruminy, Charles Herbaux, Thomas Gastinne, Corinne Haioun, Stephanie Guidez, Christophe Bonnet, Marc Andre, Liana Vereseza, Choquet Sylvain, Loic Ysebaert, Emmanuel Bachy, Fabrice Jardin, Franck Morschhauser, Vincent Ribrag

Blood (2023) 142 (Supplement 1): 853.

https://doi.org/10.1182/blood-2023-174607

Published: 2023

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy

Blood (2023) 142 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2023-182434

Published: 2023

Journal Articles

Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

Clementine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana Ben-Neriah, Katy Milne, Brad H Nelson, Andrew P. Weng, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth

Blood (2022) 140 (Supplement 1): 750–751.

https://doi.org/10.1182/blood-2022-160405

Published: 2022

Journal Articles

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Gilles Crochet, Couturier Audrey, Emmanuel Bachy, Thomas Gastinne, Guillaume Cartron, Tom Fradon, Romain Gounot, Cristina Castilla-LLorente, Clementine Sarkozy, Vincent Camus, Stéphanie Guidez, Adrien Chauchet, Eric Deconinck, Krimo Bouabdallah, Franck Morschhauser, Roch Houot

Blood (2022) 140 (Supplement 1): 4639–4641.

https://doi.org/10.1182/blood-2022-162594

Published: 2022

Journal Articles

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma

Blood (2021) 138 (Supplement 1): 450.

https://doi.org/10.1182/blood-2021-153237

Published: 2021

Journal Articles

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Michael Nissen, Xuehai Wang, Clementine Sarkozy, Aixiang Jiang, Daisuke Ennishi, Tomohiro Aoki, Stacy Hung, Elizabeth Chavez, Jeffrey W Craig, Pedro Farinha, Graham W. Slack, David W. Scott, Christian Steidl, Andrew P. Weng

Blood (2021) 138 (Supplement 1): 719.

https://doi.org/10.1182/blood-2021-154082

Published: 2021

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

NARROW

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Unraveling MCL biology to understand resistance and identify vulnerabilities

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Multi-Dimensional Molecular and Tumor-Microenvironment Analysis of Classic Hodgkin Lymphoma

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Characterization of DLBCL with a PMBL gene expression signature

Mutational landscape of gray zone lymphoma

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only